ISRCTN38768865 https://doi.org/10.1186/ISRCTN38768865

Pre- versus post-dilution haemofiltration: a prospective randomised cross-over study

Submission date	Recruitment status	[_] Prospectively registered
05/07/2005	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
06/07/2005	Completed	[_] Results
Last Edited	**Condition category**	[_] Individual participant data
14/09/2009	Urological and Genital Diseases	[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mrs Anne-Cornelie de Pont

Contact details
Academic Medical Center
Meibergdreef 9
Amsterdam
Netherlands
1105 AZ
+31 (0)20 5669111 tracer 59229
a.c.depont@amc.uva.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Acronym
PREPOST

Study objectives
Predilution prolongs extracorporeal circuit survival time during continuous venovenous hemofiltration, due to a decrease in platelet activation and thrombin generation.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Acute renal failure

Interventions
Continuous venovenous haemofiltration, predilution versus postdilution

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Extracorporeal circuit survival time

Secondary outcome measures
Platelet activation, thrombin generation, urea clearance

Overall study start date
01/12/2000

Completion date
01/01/2002

Eligibility

Key inclusion criteria
Eight critically ill patients with an indication for renal replacement therapy

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
7

Key exclusion criteria
Recent bleeding, treatment with aspirin within one week before inclusion or with therapeutic doses of unfractionated or low molecular weight heparin within 12 hours before inclusion or results of routine coagulation tests such as protrombin time (PT) and activated partial thromboplastin time (APTT) exceeding twice the upper limit of normal

Date of first enrolment
01/12/2000

Date of final enrolment
01/01/2002

Locations

Countries of recruitment
Netherlands

Study participating centre
Academic Medical Center
Amsterdam
Netherlands
1105 AZ

Sponsor information

Organisation
Academic Medical Centre (Netherlands)

Sponsor details
Prof. dr. M.B. Vroom
Academic Medical Centre
Meibergdreef 9
Amsterdam
Netherlands
1105 AZ
+31 (0)20 5669111 tracer 59155
m.b.vroom@amc.uva.nl

Sponsor type
Hospital/treatment centre

Website
http://www.amc.uva.nl

ROR
https://ror.org/03t4gr691

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Internally funded (Netherlands)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration